Floatz logo

Bcma/Gprc5D Car-T Cells

Sarcoma

Essen BiotechCell therapyPhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

91 Active assets in the Sarcoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
National Cancer Institute (NCI)
Phase 2BB
Ifosfamide
City of Hope Medical Center
Phase 3BB
Cyclophosphamide
Essen Biotech
Phase 2BB
Carboplatin
OHSU Knight Cancer Institute
Phase 2BB
Inno-206
City of Hope Medical Center
Phase 3BB

View all 50 →

Same molecule, other indications

Bcma/Gprc5D Car-T Cells is also rated in:

Sarcoma, EwingDormant
CCC
Indicative ·
48 / 100
View asset →
Sarcoma,Soft TissueDormant
CCC
Indicative ·
48 / 100
View asset →
Sarcoma, KaposiDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →